PTGX - Protagonist Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

PTGX is currently covered by 6 analysts with an average price target of $71.41. This is a potential upside of $16.97 (31.17%) from yesterday's end of day stock price of $54.44.

Protagonist Therapeutics's activity chart (see below) currently has 76 price targets and 97 ratings on display. The stock rating distribution of PTGX is 97.37% BUY and 2.63% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 79.54% with an average time for these price targets to be met of 490.5 days.

Highest price target for PTGX is $80, Lowest price target is $57, average price target is $60.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 03-Jun-2025. First documented stock forecast 06-Sep-2016.

Currently out of the existing stock ratings of PTGX, 37 are a BUY (97.37%), 1 are a HOLD (2.63%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$80

$26.66 (49.98%)

$80

22 days ago
(03-Jun-2025)

27/32 (84.38%)

$28.94 (56.68%)

284

Buy

$61

$7.66 (14.36%)

$58

3 months 15 days ago
(10-Mar-2025)

10/11 (90.91%)

$5.05 (9.03%)

170

Buy

$57

$3.66 (6.86%)

$53

3 months 21 days ago
(04-Mar-2025)

5/5 (100%)

$18.34 (47.44%)

106

Hold

$67

$13.66 (25.61%)

$51

7 months 3 days ago
(22-Nov-2024)

4/5 (80%)

$20.54 (44.21%)

653

Buy

$35

$-18.34 (-34.38%)

$35

1 years 11 months 22 days ago
(03-Jul-2023)

6/10 (60%)

$12.69 (56.88%)

1001

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is PTGX (Protagonist Therapeutics) average time for price targets to be met?

On average it took 490.5 days on average for the stock forecasts to be realized with a an average price target met ratio 79.54

Which analyst has the current highest performing score on PTGX (Protagonist Therapeutics) with a proven track record?

YASMEEN RAHIMI

Which analyst has the most public recommendations on PTGX (Protagonist Therapeutics)?

Yasmeen Rahimi works at PIPER SANDLER and has 4 price targets and 2 ratings on PTGX

Which analyst is the currently most bullish on PTGX (Protagonist Therapeutics)?

Tim Chiang with highest potential upside - $47.4

Which analyst is the currently most reserved on PTGX (Protagonist Therapeutics)?

Joseph Schwartz with lowest potential downside - -$23.34

Protagonist Therapeutics in the News

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology...

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill PN-881, a first-in-class oral peptide targeting...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?